牛牛AI助理已提取核心訊息
On January 30, 2024, Pfizer Inc. released its financial results for the fourth quarter and the full year of 2023. The announcement was made through a press release, which is now available as Exhibit 99. This information, including the press release, is furnished under Item 2.02 - Results of Operations and Financial Condition of the Form 8-K report filed with the SEC. However, it is clarified that the furnished information is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. Furthermore, the information is not to be incorporated by reference into any of Pfizer's filings under the Exchange Act or the Securities Act of 1933, except as explicitly stated in such filings.
On January 30, 2024, Pfizer Inc. released its financial results for the fourth quarter and the full year of 2023. The announcement was made through a press release, which is now available as Exhibit 99. This information, including the press release, is furnished under Item 2.02 - Results of Operations and Financial Condition of the Form 8-K report filed with the SEC. However, it is clarified that the furnished information is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. Furthermore, the information is not to be incorporated by reference into any of Pfizer's filings under the Exchange Act or the Securities Act of 1933, except as explicitly stated in such filings.
2024年1月30日，輝瑞公司發佈了第四季度和2023年全年的財務業績。該公告是通過新聞稿發佈的，該新聞稿現已作爲附錄99發佈。這些信息，包括新聞稿，是在向美國證券交易委員會提交的8-K表報告的第2.02項——經營業績和財務狀況下提供的。但是，澄清的是，就1934年《證券交易法》第18條而言，所提供的信息不被視爲 “已提交”，也不受該節規定的責任的約束。此外，除非此類文件中明確規定，否則不得以引用方式將這些信息納入輝瑞根據1933年《交易法》或《證券法》提交的任何文件中。
2024年1月30日，輝瑞公司發佈了第四季度和2023年全年的財務業績。該公告是通過新聞稿發佈的，該新聞稿現已作爲附錄99發佈。這些信息，包括新聞稿，是在向美國證券交易委員會提交的8-K表報告的第2.02項——經營業績和財務狀況下提供的。但是，澄清的是，就1934年《證券交易法》第18條而言，所提供的信息不被視爲 “已提交”，也不受該節規定的責任的約束。此外，除非此類文件中明確規定，否則不得以引用方式將這些信息納入輝瑞根據1933年《交易法》或《證券法》提交的任何文件中。
有用
沒用